GH Research (GHRS) vs Ocular Therapeutix (OCUL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GH Research (GHRS) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 25.1% versus a loss of 54.5%. Over five years, OCUL leads with a -14.8% price change compared with -21.0% for GHRS. Ocular Therapeutix is the larger company by market cap ($1.23 billion vs $1.20 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GHRS | OCUL |
|---|---|---|
| Share price | $17.53 | $5.57 |
| Market cap | $1.20B | $1.23B |
| 1-day change | -5.55% | -4.95% |
| YTD return | +38.03% | -54.12% |
| 1-year return | +25.08% | -54.49% |
| 5-year return | -21.00% | -14.83% |
| EPS (TTM) | $-0.94 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $51.95M |
| Revenue growth (YoY) | — | -18.47% |
| Net income (latest FY) | $-48.26M | $-265.94M |
| Gross margin | — | 87.35% |
| Operating margin | — | -519.75% |
| Net margin | — | -511.90% |
| 52-week high | $31.44 | $16.44 |
| 52-week low | $12.04 | $5.54 |
| Distance from 52-week high | -44.24% | -66.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +144.67% | +361.94% |
| Average volume | 294.69K | 3.03M |
| Shares outstanding | 68.68M | 220.02M |
| Employees | 73 | 325 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GHRS has outperformed OCUL by 79.6 percentage points over the past year.
About GH Research
GHRS stock →GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
GHRS vs OCUL FAQ
Which is bigger, GH Research or Ocular Therapeutix?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.23B compared with $1.20B for GH Research (GHRS).
Which stock has performed better over the past year, GHRS or OCUL?
GHRS returned +25.08% over the past 12 months, compared with -54.49% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are GH Research and Ocular Therapeutix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.